The preliminary conference programme is as follows, subject to change. Download at-a-glance version here.

Sunday 14 July 2019

11:30 - 13:30 Delegate Registration

13:30 - 15:00 Session 1: Welcome and Keynote Talk

13:30 - 14:00 Welcome and Opening Remarks

Professor Rob Bristow & Dr Natalie Cook

14:00 - 15:00 Opening Keynote Lecture
Professor Lillian Siu (Princess Margaret Hospital, Canada)
"Phase I: past and present"

15:00 - 15:30 Coffee break

15:30 - 17:00 Session 2: Debate Session

Chair: Professor Rob Bristow

The Big Debate: “This house believes every cancer patient should have comprehensive genomic profiling prior to each experimental therapy”

Debate leads: Professor Jeff Evans (Beatson Institute, UK) and Dr Tim Yap (MD Anderson, USA)


17:15 - 18:15 Welcome drinks reception for all delegates


Monday 15 July 2019

09:00 - 10:30 Session 3: Novel targets and their impact on trial designs

Chairs: Professor Duncan Jodrell, Dr Louise Carter

Professor Ruth Plummer (University of Newcastle, UK)
"Rare targets and their impact on the evolution of trial design"

Professor Sarah Blagden (University of Oxford, UK)
"The changing face of phase I trials"

Professor Pamela Munster (UCSF, USA)
"Novel targets in epigenetics"

10:30 - 11:00 Coffee break

11:00 - 12:30 Session 4: Precision Medicine

Chairs: Dr Matthew Krebs, Professor Richard Marais

Professor Caroline Dive (Cancer Research UK Manchester Institute, UK)
"Liquid Biopsy for Precision Medicine’"

Professor Gary Middleton (University of Birmingham, UK)
"The promise and pitfalls of platform trials"

Professor Steven Jones (Michael Smith Genome Sciences Centre, BC Cancer, Canada)
"Using genomics and transcriptomics to develop precision medicine in oncology in British Columbia.”


12:30 - 13:30 Lunch and poster session



13:30 - 14:30 Session 5: Keynote

Professor Skip Burris (Sarah Cannon Research Institute, USA)
“Next steps for phase I”


14:30 - 15:00 Coffee break

15:00 - 16:30 Session 6: Immuno-oncology

Chairs: Dr Anne Armstrong, Dr Elaine Kilgour


15:00 - 15:30 Dr Charles Ferté (AstraZeneca)
"Past and Current of Cancer Biological and IO Drug Development

15:30 - 16:00 Dr Santiago Zelenay (CRUK Manchester Institute, UK)
"Manipulating inflammation to raise cancer immunogenicity"

16:00 - 16:30 Dr Stefan Symeonides (University of Edinburgh, UK)
"Combination studies - immunotherapies and other targeted agents”


19:00 - Conference Dinner, Science and Industry Museum (SIM)


Tuesday 16 July 2019

07:45 Wellness 2km fun run around Manchester city centre - meet in Hotel lobby


09:00 - 12:30 PARALLEL NURSING WORKSHOP - more information here

09:00 - 10:30 Session 7: Radiotherapy combinations

Chairs: Professor Tim Illidge, Professor Kaye Williams

09:00 - 09:30 Professor Kaye Williams (The University of Manchester, UK)
"RADCOM- a consortium approach to accelerate novel drug RT combinations to clinical trials"

09:30 - 10:00 Professor Anthony Chalmers (University of Glasgow, UK)
"​Combining radiotherapy with inhibitors of the DNA damage response: are conventional phase I trials giving us the data we need?"

10:00 - 10:30 Professor Dave Raben (University of Colorado, USA)
"​The Windows of Opportunity  - Radiation and Drug Development Phase I Trials in 2019"

10:30 - 11:00 Coffee break


11:00 - 12:30 Session 8: Advanced Therapies

Chairs: Dr Fiona Thistlethwaite, Professor Robert Hawkins

11:00 - 11:30 Professor Brian Bigger (The University of Manchester, UK)
"Developing stem cell gene therapies for childhood dementias"

11:30 - 12:00 Dr Sophie Papa (King's College London, UK)
"CAR T cells and solid tumours: efficacy, toxicity and practicality"

12:00 - 12:30 Dr Reno Debets (Erasmus Medical Centre, Netherlands)
"T cells engineered with MAGE-C2 TCR to treat patients with melanoma and head-and-neck cancer: a 2019 trial in Rotterdam"


12:30 - 13:30 Lunch and poster session 


13:30 - 15:00 Session 9: Trial Design Methodology

Chairs: Professor Andrew Hughes, Professor Caroline Dive

13:30 - 14:00 Question 1

Do rules based designs offer better value (in time, cost and identifying the recommended phase II dose range(s) than model-based designs?

Percy Ivy (National Cancer Institute, USA): This conference believes that "rules based" designs offer better value

Adrian Mander (Cardiff University, UK): This conference believes that "model based" designs offer better value

14:00 - 14:30 Question 2

How can we bring phase I into the digital age?

Donal Landers (Cancer Research UK Manchester Institute): Can the patients ever become co-scientists with us in the trial?

Steffan Stringer (Foundry Health, UK): Can Investigator sites ever become digital hubs?

14:30 - 15:00 Question 3

What is the primary purpose of phase I?

Udai Banerji (ICR, London, UK): The primary purpose is to define a recommended dose range for phase 2

Glen Clack (University of Sheffield, UK): The primary purpose is to achieve drug registration through modular trial designs


15:00 Session 10: Closing Remarks Professor Andrew Hughes